Daily Upgrade Trial
University of North Carolina, Chapel Hill · with Sportiv, Inc. · NCT07792603
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 25–45 · Women only
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 44
- US sites recruiting
- 1
- Study start
- August 31, 2026
- Record last updated
- September 3, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This study evaluates the acute and chronic effects of an essential amino acid supplement (Daily Upgrade EAA+) on metabolomics, amino acid kinetics, metabolic rate, body composition in active adult women. The study consists of an acute randomized double-blind crossover phase comparing EAA+, whey protein isolate, and placebo before high-intensity interval training (HIIT), and a chronic randomized double-blind parallel-arm phase evaluating 3 weeks of EAA+ or placebo supplementation combined with twice-weekly HIIT.
Being studied: Essential Amino Acid+; Non-Calorie Placebo; High intensity Interval Training; No Exercise
Conditions: Healthy Women
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Participant is an adult between the ages of 25-45 years
- Participant has a recorded BMI between 18.5-30 kg/m\^2
- Participant is apparently healthy and free from disease, as determined by a health history questionnaire
- Participant is a biological female
- Participant is naturally menstruating or uses a form of hormonal contraceptive
- Participant is recreationally active, based on the International Physical Activity Questionnaire- Short Form
- Participant agrees to abstain from caffeine (12 hours), tobacco, alcohol, and exercise for 24 hours prior to testing days
- Participant is willing and able to comply with the protocol
Exclusion Criteria
- Participant has been diagnosed with chronic heart disease, arrhythmias, thyroid disease, renal, hepatic, autoimmune or neurological diseases, as determined by a health history questionnaire.
- Participant has a musculoskeletal disorder or injury that would prohibit them from being able to safely complete the study protocol.
- Participant is currently enrolled in a separate clinical trial or weight loss program involving diet, exercise, physical activity, or the potential ingestion of an active drug or dietary supplement
- Participant is using, or has consistently used one of the following dietary supplements within 1 month prior to enrollment: whey protein, creatine, essential amino acids
- Participant has a known allergy or sensitivity to the placebo or active ingredients
- Participant is pregnant or planning to become pregnant
- Participant does not speak English or is hearing impaired
Recruiting US locations
Applied Physiology Laboratory
Chapel Hill, NC 27599
Site contact: Research Coordinator · 919-962-1663 · aplresearch@unc.edu
Study contacts (from the official record)
- Abbie Smith-Ryan, PhD · 919-962-2574 · abbiesmith@unc.edu
- Research Coordinator · 919-962-1663 · aplresearch@unc.edu
Similar studies in North Carolina
All nutrition & metabolism studies in North Carolina →- RecruitingPhase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Hoffmann-La Roche
- Location
- Charlotte, NC + 121 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Hoffmann-La Roche
- Location
- Asheville, NC + 112 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Boehringer Ingelheim
- Location
- Fayetteville, NC + 123 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity
Opus Genetics, Inc
- Location
- Garner, NC + 19 other US sites
- Eligibility basics
- Ages 18+